Aurinia Pharmaceuticals Inc (AUPH)

NASDAQ
Currency in USD
8.240
+0.120(+1.48%)
Closed·
After Hours
8.2400.000(0.00%)
·
AUPH Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected tomorrow
Fair Value
Day's Range
8.0158.340
52 wk Range
4.99010.670
Key Statistics
Edit
Prev. Close
8.12
Open
8.02
Day's Range
8.015-8.34
52 wk Range
4.99-10.67
Volume
1.05M
Average Volume (3m)
1.4M
1-Year Change
62.08%
Book Value / Share
2.64
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AUPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.833
Upside
+19.34%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

Aurinia Pharma Company Profile

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc Earnings Call Summary for Q4/2024

  • Q4 2024 EPS of $0.01 missed $0.03 forecast; revenue of $59.9M fell short of $61.7M projection, leading to 4.65% stock drop
  • 2024 total revenue up 34% YoY to $235.1M; LUKINIS net sales reached $216.2M, a 36% increase from 2023
  • 2025 guidance: total revenue $250-260M, net product sales $240-250M; company advancing pipeline, particularly AUR200
  • Strong liquidity with $358.5M cash/investments; cash flow from operations $44.4M for 2024; current ratio 5.6
  • CEO emphasized historical results provide insight for projections; company preparing for potential generic competition
Last Updated: 27-02-2025, 08:02 pm
Read Full Transcript

Compare AUPH to Peers and Sector

Metrics to compare
AUPH
Peers
Sector
Relationship
P/E Ratio
193.0x−2.2x−0.5x
PEG Ratio
1.800.000.00
Price/Book
2.9x2.0x2.6x
Price / LTM Sales
4.7x11.1x2.9x
Upside (Analyst Target)
23.2%299.4%56.4%
Fair Value Upside
Unlock14.0%9.3%Unlock

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 9.833
(+19.34% Upside)

Earnings

Latest Release
Feb 27, 2025
EPS / Forecast
0.01 / 0.03
Revenue / Forecast
59.90M / 61.70M
EPS Revisions
Last 90 days

FAQ

What Is the Aurinia Pharma (AUPH) Stock Price Today?

The Aurinia Pharma stock price today is 8.24.

What Stock Exchange Does Aurinia Pharma Trade On?

Aurinia Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Aurinia Pharma?

The stock symbol for Aurinia Pharma is "AUPH."

What Is the Aurinia Pharma Market Cap?

As of today, Aurinia Pharma market cap is 1.13B.

What is Aurinia Pharma Earnings Per Share?

The Aurinia Pharma EPS is 0.04.

What Is the Next Aurinia Pharma Earnings Date?

Aurinia Pharma will release its next earnings report on 30 Apr 2025.

From a Technical Analysis Perspective, Is AUPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.